Literature DB >> 31567643

Treatment of Catatonia in Frontotemporal Dementia: A Lesson From Zolpidem Test.

Mohammad Sayadnasiri1, Farzaneh Rezvani2.   

Abstract

BACKGROUND: During recent years, zolpidem presents a potential but transient treatment option for a large variety of neurologic conditions. Although most cases had disorders of consciousness or movement disorders, there are few reports of beneficial effects of zolpidem on language function. CASE: We present a case of frontotemporal dementia who developed catatonia during her disease course and her refractory speech problem showed dramatic response to zolpidem.
CONCLUSIONS: In dementia patients, different catatonic symptoms may show differential responses to the therapeutic agents and, if verbal symptoms are dominant, it is worthy to try zolpidem in the early stage.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31567643     DOI: 10.1097/WNF.0000000000000362

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Emerging Treatments for Disorders of Consciousness in Paediatric Age.

Authors:  Hassna Irzan; Marco Pozzi; Nino Chikhladze; Serghei Cebanu; Artashes Tadevosyan; Cornelia Calcii; Alexander Tsiskaridze; Andrew Melbourne; Sandra Strazzer; Marc Modat; Erika Molteni
Journal:  Brain Sci       Date:  2022-01-31

2.  Catatonia in older adults: A systematic review.

Authors:  Walter Jaimes-Albornoz; Angel Ruiz de Pellon-Santamaria; Ayar Nizama-Vía; Marco Isetta; Ines Albajar; Jordi Serra-Mestres
Journal:  World J Psychiatry       Date:  2022-02-19

3.  A Retrospective Analysis on Clinical Practice-Based Approaches Using Zolpidem and Lorazepam in Disorders of Consciousness.

Authors:  Bei Zhang; Katherine O'Brien; William Won; Sheng Li
Journal:  Brain Sci       Date:  2021-05-29

4.  Case Report: Catatonic Stupor in Behavioral Variant Frontotemporal Dementia.

Authors:  Gustavo Campos de França; Henrique Carneiro de Barros Barreto; Thiago Paranhos; Julio Cesar Nunes; Ricardo de Oliveira-Souza
Journal:  Front Neurol       Date:  2022-01-18       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.